Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20408407 | 0.90 | ACE (0.46) | ACEMETAP2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10974704 | 0.85 | ACE (0.41) | ACEMETAP2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7015409 | 0.82 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2D6CYP2C19TRPA1 | |
| SCHEMBL16181502 | 0.82 | TRPA1 (0.46) | ACEMETAP2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL23260283 | 0.82 | ACHE (0.36) | ACECYP1A2 | |
| SCHEMBL25636408 | 0.82 | ACHE (0.36) | ACEMETAP2CYP1A2 | |
| SCHEMBL12610440 | 0.82 | CYP1A2 (0.41) | ACEMETAP2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9906029 | 0.81 | ACE (0.46) | ACEMETAP2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27820037 | 0.81 | ESR1 (0.42) | ACECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL14525778 | 0.78 | CYP2D6 (0.46) | ACEMETAP2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018058029-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-8198318-B2 | Therapeutic amides | ALLERGEN, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-7879854-B2 | 2-morpholin-4-ylethyl 5-[3-[(2S)-1-[4-(1-hydroxyhexyl)phenyl]-5-oxopyrrolidin-2-yl]propyl]thiophene-2-carboxylate, useful in treating vision defects, inflammatory bowel disease and alopecia | ALLERGAN, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7737140-B2 | Eicosanoid derivatives used in the treatment of glaucoma, inflammatory bowel disease and alopecia | ALLERGAN, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090286787-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090270396-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090239858-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239858-A1 | THERAPEUTIC AMIDES | ACER2, SLC10A1, ASAH2 | ACE 89/4885METAP2 2134/4885CYP1A2 1950/4885 |
| US-20090286787-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | ACE 230/4885METAP2 2090/4885CYP1A2 1762/4885 |
| US-20090270396-A1 | THERAPEUTIC COMPOUNDS | SLC10A1, ABCB11, ASAH2 | ACE 683/4885METAP2 2300/4885CYP1A2 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.